Levodopa/Carbidopa/Entacapone Orion


levodopa / carbidopa / entacapone

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR) for Levodopa/Carbidopa/Entacapone Orion. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Levodopa/Carbidopa/Entacapone Orion.

This EPAR was last updated on 16/01/2023

Authorisation details

Product details
Levodopa/Carbidopa/Entacapone Orion
Agency product number
Active substance
  • levodopa
  • carbidopa
  • entacapone
International non-proprietary name (INN) or common name
  • levodopa
  • carbidopa
  • entacapone
Therapeutic area (MeSH)
Parkinson Disease
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Orion Corporation
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Orionintie 1
FI-02200 Espoo

Product information

12/01/2023 Levodopa/Carbidopa/Entacapone Orion - EMEA/H/C/002441 - IG/1580

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Nervous system

Therapeutic indication

Levodopa/Carbidopa/Entacapone Orion is indicated for the treatment of adult patients with Parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa / dopa-decarboxylase (DDC)-inhibitor treatment.

Assessment history

How useful was this page?

Add your rating